Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
1.940
-0.030 (-1.52%)
At close: Oct 17, 2025, 4:00 PM EDT
1.950
+0.010 (0.52%)
After-hours: Oct 17, 2025, 7:59 PM EDT
Milestone Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
33
Market Cap
189.94M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.00M | -4.00M | -80.00% |
| Dec 31, 2022 | 5.00M | -10.00M | -66.67% |
| Dec 31, 2021 | 15.00M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
MIST News
- 8 days ago - Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025 - GlobeNewsWire
- 2 months ago - Milestone® Pharmaceuticals to Present at Upcoming Conferences - GlobeNewsWire
- 2 months ago - Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update - GlobeNewsWire
- 3 months ago - Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution - Seeking Alpha
- 3 months ago - Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge - Benzinga
- 3 months ago - Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants - GlobeNewsWire
- 3 months ago - Milestone Pharmaceuticals Announces Proposed Public Offering - GlobeNewsWire
- 3 months ago - Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray - GlobeNewsWire